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ABSTRACT
Herein, we evaluated whether Placental Mesenchymal Stromal Cells (PDMSCs) derived from normal and
Preeclamptic (PE) placentae presented differences in the expression of G1/S-phase regulators p16INK4A,
p18INK4C, CDK4 and CDK6. Finally, we investigated normal and PE-PDMSCs paracrine effects on JunB,
Cyclin D1, p16INK4A, p18INK4C, CDK4 and CDK6 expressions in physiological term villous explants.
PDMSCs were isolated from physiological (n D 20) and PE (n D 24) placentae. Passage three normal and
PE-PDMSC and conditioned media (CM) were collected after 48h. Physiological villous explants (n D 60)
were treated for 72h with normal or PE-PDMSCs CM. Explants viability was assessed by Lactate
Dehydrogenase Cytotoxicity assay. Cyclin D1 localization was evaluated by Immuofluorescence (IF) while
JunB, Cyclin-D1 p16INK4A, p18INK4C, CDK4 and CDK6 levels were assessed by Real Time PCR and Western
Blot assay.
We reported significantly increased p16INK4A and p18INK4C expression in PE- relative to normal PDMSCs
while no differences in CDK4 and CDK6 levels were detected. Explants viability was not affected by normal
or PE-PDMSCs CM. Normal PDMSCs CM increased JunB, p16INK4 and p18INK4C and decreased Cyclin-D1 in
placental tissues. In contrast, PE-PDMSCs CM induced JunB downregulation and Cyclin D1 increase in
placental explants. Cyclin D1 IF staining showed that CM treatment targeted mainly the syncytiotrophoblast.
We showed Cyclin D1-p16INK4A/p18INK4C altered pathway in PE-PDMSCs demonstrating an aberrant
G1/S phase transition in these pathological cells. The abnormal Cyclin D1-p16INK4A/p18INK4C expression
in explants conditioned by PE-PDMSCs media suggest a key contribution of mesenchymal cells to the






Eukaryotic cell cycle progression is dependent on a tightly
regulated activity of Cyclins (Cyclins A, B, D, E) and Cyclin-
Dependent Kinases (CDK1, CDK2, CDK4, CDK6). Upon receiv-
ing external stimuli to divide, cells up-regulate CDKs and their
activating Cyclins to orchestrate the complex proliferation pro-
cesses. CDKs activities are in turn regulated by the abundance of
Cyclins and by the interaction with CDK-inhibitory proteins
(CKIs).1-3 A finely tuned cell cycle progression is pivotal for
proper human placental development and functionality, in order
to guarantee embryo growth and pregnancy success. Human pla-
centation involves high trophoblast proliferation rate and tro-
phoblast invasion of the uterine wall.4,5 The balance between
trophoblast proliferative/invasive phenotypes is controlled by
complex interactions among cell cycle promoters and inhibitors6
that are seriously compromised in case of severe placenta-related
disorders as Preeclampsia.7 PE represents the main cause of feto-
maternal mortality and morbidity worldwide. affecting about 5–
8% of all pregnancies. It is characterized by immature hyper-
proliferative trophoblast phenotype, shallow trophoblast invasion
of maternal spiral arteries8 and aberrant cell cycle progression of
placental mesenchymal cells (Placenta-derived Mesenchymal
Stromal Cells - PDMSCs)9,10 a unique population stem cells-like
features and key immune-regulatory properties.9-12
During early placentation, mesenchymal cells represent the
structural support for the forming primary villi and drive placen-
tal capillary network establishment.13 Our recent findings on
JunB-mediated inhibition of Cyclin D1 in preeclamptic
PDMSCs10 lead to the hypothesis that PE-PDMSCs, as previously
demonstrated for the trophoblast, may present defects that could
cause/contribute to the aberrant placenta development of pre-
eclamptic placentae.7 The Activating Protein 1 (AP-1) family
member JunB is well known as a cell division inhibitor14,15 and
senescence inducer.15 JunB is able to inhibit the G1/S phase tran-
sition by inducing Cyclin-D1 downregulation10 and promoting
the expression of the cell-cycle kinase inhibitor p16INK4A.15
Importantly, the G1/S phase is cooperatively regulated by CDK 4
and 6 whose activities are in turn constrained by CKIs p16INK4A
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and p18INK4C, that specifically inhibit the formation of CDKs-
Cyclin D1 complexes.3 In quiescent cells, p16INK4A and p18INK4C
are in excess to Cyclin D1–CDK4/6 complexes thus maintaining
cells in a non-proliferating state.15 Mitogen stimulation leads to
Cyclin D1 synthesis and, as soon as the CKI inhibitory threshold
is overcome, cyclin–CDK kinase activity promotes cell cycle pro-
gression into S phase.15 CKIs are therefore critical mediators of
antiproliferative signals that arrest the cell cycle and allow DNA
repair, terminal differentiation and senescence.15 Moreover,
Cyclin D1 controls CDK4 and CDK6 activities acting as a positive
coactivator16 and when its signal is not strong enough to enhance
CDK4 and CDK6 activities, cells cannot enter into S phase.17
In the present study, we characterized the expression of
p16INK4A, p18INK4C, CDK4 and CDK6 in normal and PE-
PDMSCs. Since mesenchymal stromal cells could influence pro-
liferation and apoptosis in neighboring cells,9,18,19 we investi-
gated the paracrine effect of normal and PE-PDMSCs on JunB,
CyclinD1, p16INK4A, p18INK4C, CDK4 and CDK6 expressions in
physiological term placental villi. Thus, we increased our knowl-
edge on PDMSCs cell cycle regulation and on their contribution
to both physiological and pathological placentation.
Results
Study population
Clinical features of the study population were reported in
Table 1. Normal (n D 20) and PE (n D 24) pregnancies were
comparable for maternal age, while gestational age (p < 0.01,
0.85 Fold Decrease), neonatal and placental weights at delivery
were, as expected, significantly lower in PE group vs controls (p
 0.01). All pregnancies belonging to the PE group presented
abnormal umbilical (59%) and/or uterine arteries (76%)
Doppler velocimetry and 66% of them presented FGR.
Characterization of placenta-derived MSCs
All PDMSCs cell lines (n D 44) presented proper mesenchymal
stromal phenotype as assessed by flow cytometry. Cells were
positive for CD105, CD166, CD90, CD73 and negative for
HLA-II, for haematopoietic markers CD34 and CD45 and
endothelial progenitor markers CD133 and CD31. Normal and
PE PDMSCs were also negative for B cells, neutrophils and
macrophages markers CD20 and CD14 and for trophoblast
and epithelial marker CD326, thus excluding any type of con-
tamination (data not shown). RT-PCR detected the expression
of typical stemness markers Oct-4 and Nanog, in all PDMSCs
cell lines (n D 44) (data not shown).
P16INK4A, p18INK4C, CDK4 and CDK6 expressions in normal
and PE-PDMSCs
We previously demonstrated that JunB overexpression in PE-
PDMSCs affects cell cycle progression by inducing Cyclin-D1
downregulation.10 We next investigated the expression of
p16INK4A, p18INK4C, CDK4 and CDK6 in normal and PE-
PDMSCs in order to complete the characterization of the G1/S
regulatory pathway headed by Cyclin D1. We showed that
Cyclin D1 post-translational inhibitors p16INK4A (p D 0.01,
1.73 Fold Increase) and p18INK4C (p D 0.04, 2.74 Fold Increase)
mRNA levels were significantly higher in PE- relative to normal
PDMSCs (Fig. 1a and b left panel). overexpression of p16INK4A
(p D 0.011, 2.09 Fold Increase) and p18INK4C (p < 0.01, 2.81
Fold Increase) in PE-PDMSCs were confirmed at the protein
level (Fig. 1a and b right panel). No differences were found in
CDK4 and CDK6 expression between normal and PE-PDMSCs
(p > 0.05, Fig. 2a and b).
PDMSCs conditioned media did not alter physiological
term placental villous explants viability
In order to evaluate whether PDMSCs CM affect cell viability of
treated physiological term villous explants, the Lactate dehy-
drogenase (LDH) assay, which assessed the cell membrane
integrity by measuring the LDH leakage from cells, was per-
formed. After 72h of treatment, we observed that the relative
LDH amount released into the media was comparable among
unconditioned media treated explants and those treated by nor-
mal or PE-PDMSCs CM (p > 0.05, Fig. 3). Importantly, all CM
LDH levels were significantly lower compare with the consid-
ered cytotoxicity cut-off of 54% (p < 0.05, Fig. 3).
PDMSCs conditioned media affects JunB, Cyclin D1,
p16INK4A, p18INK4C, CDK4, CDK6 and PARP1 expressions in
physiological term placental villous explants
PDMSCs exert most of their functions by secreting soluble
mediators. Therefore, we cultured physiological term villous
explants with CM derived from normal or PE-PDMSCs and we
investigated the expression of JunB, Cyclin D1, p16INK4A,
p18INK4C, CDK4 and CDK6. Moreover, we evaluated pro-apo-
ptotic PARP1 expression as marker of programmed cell death
in treated explants. Normal PDMSCs CM induced overexpres-
sion of JunB mRNA (p D 0.01, 1.72 Fold Increase) and protein
(p D 0.04, 1.38 Fold Increase) levels (Fig. 4a) and a significant
decrease in Cyclin D1 mRNA (p D 0.03, 0.62 Fold Decrease)
and protein (p D 0.05, 0.49 Fold Decrease) levels relative to
unconditioned media (Fig. 4b). In stark contrast, PE-PDMSCs
CM promoted a significant downregulation in JunB expression
Table 1. Clinical features of the study population. Comparison s of normal (N,
n D 20) and PE (PE, n D 24) pregnancies clinical features. Statistical significance ()
has been considered as p < 0.05.
Normal (n D 20) Preeclampsia (n D 24)
Nulliparae (%) 30 41.6
Gestational age at delivery (weeks) 39.5 § 1.08 (37–41) 33.6 § 3.30 (28–41)
Maternal age at delivery (years) 33.1 § 4.54 (24–41) 33.4 § 5.63
Caucasian ethnicity (%) 100 100
Smokers (%) 10 —
Alcohol (%) 15 —
Previous prenatal admission (%) 10 33.3
Systolic blood pressure (mm Hg) 114.7 § 14.18 150 § 19.41
Diastolic blood pressure (mm Hg) 73 § 10 95 § 12.18
Proteinuria (g/24h) Absent 2.92 § 4.57
A/REDF (%) 0 58.3
Pathological uterine doppler (%) 0 75
Labor (%) 60 25
Caesarian section (%) 55 87.5
Maternal oxygen given at delivery (%) — 25
Birth weight (g) 3530.5 § 379.54 AGA (n D 8): 2490 § 845.3





(p D 0.03, 2.12 Fold Decrease) followed by Cyclin D1 upregula-
tion (mRNA: p D 0.03, 1.52 Fold Increase; protein: p D 0.05,
1.56 Fold Increase) (Fig. 4a and b). Moreover, normal PDMSCs
CM promoted p16INK4A and p18INK4C mRNA (p D 0.05, 1.66
Fold Increase; p D 0.04, 1.91 Fold Increase respectively) and
protein (p D 0.02, 1.78 Fold Increase; p D 0.04, 1.60 Fold
Increase respectively) expression relative to control explants
(Fig. 5a and b). There were no significant effects on p16INK4A
and p18INK4C expression after PE-PDMSCs CM treatment
(Fig. 5a and b). Despite a trend of increase in CDK4 levels in
normal PDMSCs CM explants, we showed that neither normal
nor PE conditioned medium had significant effects on CDK4
and CDK6 expression (Fig. 6a and b). Finally, we found no
significant differences in PARP1 expression levels between
untreated controls and normal PDMSCs CM explants while
PE-PDMSCs CM induced PARP-1 mRNA (p D 0.024, 2.3 Fold
Increase) and protein (2.5 Fold Increase) overexpression
relative to unconditioned media (Supplementary Figure S1a
and b).
In order to clarify which placental cell population was tar-
geted by PDMSC CM, we performed Cyclin D1 immufluores-
cence (IF) staining on the villous explants treated as explained
above. Cyclin D1 staining was mostly localized in the syncytio-
trophoblast (TR) layer (Fig. 7), thus identifying TR cells as the
main PDMSCs CM target. A weak positivity for Cyclin D1 was
found in mesenchymal (M) and perivascular cells (Fig. 7).
Importantly, IF confirmed RNA and protein data. Immunore-
activity for Cyclin D1 was markedly decreased in the TR cyto-
plasm and peri-nuclear areas in normal PDMSCs CM villous
explants (Fig. 7c). In stark contrast, Cyclin D1 signal was
increased in PE-PDMSCs CM villous explants (Fig. 7d).
Discussion
In the present study, we described, for the first time to our
knowledge, the aberrant expressions of G1/S cell cycle transi-
tion regulators in preeclamptic chorionic mesenchymal stromal
cells. We reported a significant overexpression of Cyclin D1
Figure 1. p16INK4A and p18INK4C gene and protein expression in normal vs preeclamptic PDMSCs. (a) mRNA (left panel) and protein (right panel) expression of p16INK4A in
normal (N, n D 20) and PE-PDMSCs (PE, n D 24) (b) mRNA (left panel) and protein (right panel) expression of p18INK4C in normal (N, n D 20) and PE-PDMSCs (PE, n D 24).
Statistical significance () has been considered as p < 0.05.
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inhibitors p16INK4A and p18INK4C in PE-PDMSCs, thus empha-
sizing the presence of major alterations in Cyclin D1 regulatory
pathway in this specific placental cell population. Using physio-
logical term villous explants and PDMSCs conditioned media,
we demonstrated that normal and preeclamptic mesenchymal
cells differentially modulate the expression of G1/S regulators
in the placental tissue via paracrine interactions. Normal
PDMSCs promoted JunB, p16INK4A and p18INK4C expression
and Cyclin D1 downregulation, while preeclamptic PDMSCs
induced JunB downregulation accompanied by Cyclin D1 and
PARP1 overexpression in physiological placental tissue. Our
data strengthen the concept that PDMSCs, along with the well-
established trophoblast anomalies, could cause or contribute to
the pathological placental alterations typical of preeclampsia.
Cyclin D1 is a cell cycle regulator specific for the G1/S phase
that, by binding and activating CDK4 and CDK6, promotes
DNA synthesis and cell proliferation. During physiological pla-
centation, cytotrophoblast and extravillous trophoblast cells
express Cyclin D1 while it is downregulated in placentae from
preeclamptic pregnancies.20,21 Besides the trophoblast,
Figure 2. CDK4 and CDK6 gene and protein expression levels in normal vs preeclamptic PDMSCs. (A) mRNA (left panel) and protein (right panel) expression of CDK4 in
normal (N, n D 20) and PE-PDMSCs (PE, n D 24) (B) (b) mRNA (left panel) and protein (right panel) expression of CDK6 in normal (N, n D 20) and PE-PDMSCs (PE, n D
24). Statistical significance () has been considered as p < 0.05.
Figure 3. PDMSCs conditioned media effect on physiological term placental villous
explants viability. Positive control (C) was provided by the kit. Explants treated by
Triton X-100 and by unconditioned culture media for 8 h were used as high (H)
and low controls respectively. Cytotoxicity in 72h supernatant of physiological vil-
lous explants treated with unconditioned media (CTRL) or media conditioned by
normal (N CM) and preeclamptic (PE CM) PDMSCs was assessed by LDH assay. Sta-
tistical significance () has been considered as p < 0.05.
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mesenchymal stromal cells resident in both chorionic villi and
decidua are actively involved in the impaired placenta develop-
ment typical of PE.9,10,22-24 In line with PE trophoblast, we pre-
viously reported that chorionic PE-PDMSCs are characterized
by JunB-mediated Cyclin D1 downregulation,10 stressing the
importance of preeclampsia-related G1/S transition anomalies.
In the present study, we added another important piece to the
intricate puzzle of PE pathogenesis, describing a significant
increase of p16INK4a and p18INK4C in preeclamptic PDMSCs.
These molecules are G1-specific inhibitors of Cyclin D1-
CDK4/6 complex formation that restrain CDKs mitogenic
activity.25-27 In accordance with our model, JunB expression
induced p16INK4a and p18INK4C accumulation and consequent
inhibition of Cyclin D1-associated activities in mouse embry-
onic fibroblasts, resulting in G1-phase extension and reduced
cell proliferation.15, 28
Cell cycle arrest and altered expression of growth regulatory
proteins p16INK4a and p18INK4C are key features of senescence,
critical cellular response to environmental insults typical of the
preeclamptic placental setting as oxidative stress and cytokines
stimulation.29,30 We previously reported an increased number
of slow proliferating senescent PDMSCs in PE placentae, char-
acterized by enhanced senescence-associated b-galactosidase
activity.9 Increased mesenchymal cells senescence was
described in the bone marrow of patients affected by systemic
lupus erythematosus,31 clinical condition often associated to
preeclampsia and characterized as well by hypertension, immu-
nological impairment and exacerbated systemic inflammation.
Thus, the dramatic increase of p16INK4a and p18INK4C described
in the present study could be interpreted as a cause or conse-
quence of the pathological preeclamptic milieu in which chori-
onic mesenchymal cells developed.
Importantly, cell cycle is related to placental age and it was
described that placental cell proliferation declines throughout
the 3 trimesters of pregnancy.32 Therefore, it could be expected
a lower expression of cell cycle inhibitors in younger pre-term
PE-PDMSCs relative to term cells. Indeed, the over-accumula-
tion of p16INK4A and p18INK4C in pre-term PE-PDMSCs
Figure 4. JunB and Cyclin D1 gene and protein expression levels in physiological placental villous explants treated with culture media conditioned by normal or PE-
PDMSC. (A)JunB mRNA (left panels) and protein (right panels) expression levels in physiological villous explants treated with unconditioned media (CTRL, nD 16 explants)
or media conditioned by normal (N CM, n D 16 explants) and preeclamptic (PE CM, n D 16 explants) PDMSCs as assessed by Real Time PCR and Western Blot analysis. B)
Cyclin D1 mRNA (left panels) and protein (right panels) expression levels in physiological villous explants treated with unconditioned media (CTRL, n D 16 explants) or
media conditioned by normal (N CM, nD 16 explants) and preeclamptic (PE CM, nD 16 explants) PDMSCs as assessed by Real Time PCR and Western Blot analysis. Statis-
tical significance () has been considered as p < 0.05.
204 A. M. NUZZO ET AL.
described herein appears an even more significant anomaly of
these pathological cells.
As mentioned above, p16INK4a and p18INK4C act by inhibit-
ing Cyclin D1-CDK4/6 complex formation. Herein, we didn’t
find differences in CDK4 and CDK6 expression between nor-
mal and PE-PDMSCs. These data are consistent with previous
work by Hara and colleagues that, upon senescence, showed
increased p16INK4A and p18INK4C but no effects in CDK4 and
CDK6 expression on human cultured fibroblasts.33
In contrast to the early paradigm of cell replacement and
differentiation as a therapeutic mechanism of action, increasing
evidence suggests that MSCs trophic mediators are responsible
for their positive impact on tissue damage.34 They include bio-
active soluble factors known to inhibit apoptosis, fibrosis and
inflammation, to enhance angiogenesis, to stimulate mitosis
and/or differentiation of tissue-intrinsic progenitor cells.35
Moreover, PDMSCs are able to modulate the immune response
in an autocrine and/or paracrine manner.36-38 It was previously
shown that MSC-mediated immunosuppression is produced
via an anti-proliferative action whereby cells of lymphoid and
myeloid lineage are arrested at early stages of cell cycle.39 The
MSC-mediated cell cycle regulation is also supported by co-cul-
ture experiments where mesenchymal cells are able to arrest
cancer cell cycle in the G0/G1 phase.19,40 Furthermore, in vitro
and in vivo studies on human BV173 acute lymphoblastic leu-
kemia cells and on rat hepatic stellate cells demonstrated that
the MSCs-induced cell cycle arrest is mediated by downregula-
tion of Cyclin D1, Cyclin D2, Cyclin H accompanied by expres-
sion of negative regulators as p15INK4B, p16INK4A and
p18INK4C and p21WAF1/Cip1.19,41 Indeed, PDMSCs could as
well modulate the expression of trophoblast cell cycle regula-
tors. We reported a significant Cyclin D1 downregulation and
p16INK4A/p18INK4C upregulation in physiological villous
explants treated by normal PDMSCs-CM. Our data suggest
that normal PDMSCs modulate cell cycle regulators as MSC
from other sources. In contrast to the generally accepted idea
Figure 5. P16INK4A and p18INK4C gene and protein expression levels in physiological placental villous explants treated with culture media conditioned by normal or PE-
PDMSC. (A) P16INK4A mRNA (left panels) and protein (right panels) expression levels in physiological villous explants treated with unconditioned media (CTRL, n D 16
explants) or media conditioned by normal (N CM, n D 16 explants) and preeclamptic (PE CM, n D 16 explants) PDMSCs as assessed by Real Time PCR and Western Blot
analysis. B) and p18INK4C mRNA (left panels) and protein (right panels) expression levels in physiological villous explants treated with unconditioned media (CTRL, n D 16
explants) or media conditioned by normal (N CM, n D 16 explants) and preeclamptic (PE CM, n D 16 explants) PDMSCs as assessed by Real Time PCR and Western Blot
analysis. Statistical significance () has been considered as p < 0.05.
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that the increased senescence is a key contributor in altered pla-
cental development, it was described that senescent cells may be
important for placental physiological functions during preg-
nancy. The induction of trophoblast cells senescence contrib-
utes to cytokines production that is mandatory for normal
placental function. Moreover, trophoblast senescence attracts
NK cells pivotal for functional maternal/fetal interface and it
maintain cell cycle arrest supporting cell viability.42 The
absence of cellular senescence triggers apoptosis and macro-
phage infiltration to correct the imbalance in cell population.42
Thus, PDMSCs, through the modulation of senescence
inducers p16INK4A and p18INK4C, might play a crucial role in
physiological placental development maintaining and preserv-
ing the normal placental function and homeostasis. Recent pre-
clinical studies on melanoma showed that loss-of-function of
proteins as p16INK4A promote the expression and activation of
CDK4 and CDK6.43 Since normal PDMSCs-CM induced a sig-
nificant p16INK4A upregulation, we then examined CDKs
expression levels. In contrast to previous data, in our model
there was not a p16INK4A-CDK4/6 correlation. In fact, p16INK4A
upregulation induced by normal PDMSCs-CM did not affect
CDK4 and CDK6 expression suggesting a different control
mechanisms mediated by chorionic MSCs. Our results are con-
sistent with reports that demonstrated no detectable changes in
the expression of CKDs in B16 melanoma cells treated with
media conditioned by adipose mesenchymal stem cells.44
Recently it has been shown that bone marrow MSCs condi-
tioned medium modulates the Activating Protein 1 (AP-1) sig-
naling pathway.45 Even Wharton’s jelly-derived MSC
conditioned medium regulates cell cycle by triggering the AP-1
pathway in human airway epithelial cells.46 Herein we found
that normal PDMSCs-CM induced JunB upregulation and con-
sequent Cyclin D1 downregulation in physiological term villous
explants. We recently reported that the AP-1 family member
JunB specifically controls Cyclin D1 transcriptional regulation
in PDMSCs.10 The modulation of Cyclin D1 as well as Cyclin
D1 inhibitors is one of the most common strategies used by
MSC to face adverse conditions.41 In the placental context, it
Figure 6. CDK4and CDK6 gene and protein expression levels in physiological placental villous explants treated with culture media conditioned by normal or PE-PDMSC.
(A) CDK4 mRNA (left panels) and protein (right panels) expression levels in physiological villous explants treated with unconditioned media (CTRL, n D 16 explants) or
media conditioned by normal (N CM, n D 16 explants) and preeclamptic (PE CM, n D 16 explants) PDMSCs as assessed by Real Time PCR and Western Blot analysis. B)
CDK6 mRNA (left panels) and protein (right panels) expression levels in physiological villous explants treated with unconditioned media (CTRL, n D 16 explants) or media
conditioned by normal (N CM, nD 16 explants) and preeclamptic (PE CM, nD 16 explants) PDMSCs as assessed by Real Time PCR and Western Blot analysis. Statistical sig-
nificance () has been considered as p < 0.05.
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could be used by normal PDMSCs to counteract spontaneous
apoptosis associated with trophoblast proliferation, thus main-
taining tissue homeostasis.47 In line with this hypothesis, we
reported that after treatment with normal PDMSCs CM, apo-
ptotic marker PARP-1 expression levels were comparable with
those of physiological explants treated with unconditioned
media.
MSC’s homeostatic functions, exerted through both para-
crine and contact-dependent mechanisms, were widely
described in other tissues.48,49 In particular, bone marrow
MSCs prevented oxidative metabolism thus protecting the
neighboring neutrophils from apoptosis.50 Altered expression
of G1/S cell-cycle modulators accounts for the aberrant tropho-
blast proliferation/apoptosis rheostat typical of preeclampsia,
leading to trophoblast debries release into the maternal circula-
tion. This disturbance of trophoblast homeostasis produces del-
eterious effects on placental functionality.51 We next tested the
hypothesis that medium conditioned by preeclamptic PDMSCs
could disrupt placental homeostasis by altering the expression
of trophoblast cell cycle regulators in physiological tissues.
As mentioned above, senescence could function as a pro-
tective mechanism that limits trophoblasts proliferation, thus
maintaining cell viability and giving cells resistance to apopto-
sis.52 If this mechanism fails, persisting damaged cells could
induce tissue damage.52 Importantly, senescence markers were
found in term placentae and they were interpreted as a sign of
physiological aging.53 Herein, we reported that term physio-
logical placental explants treated by preeclamptic PDMSCs
conditioned medium were characterized by increased prolifer-
ation and apoptosis, as indicated by cyclin D1 increase accom-
panied by JunB downregulation and PARP1 increase. Our
data emphasize the ability of PE-PDMSCs to significantly
perturb the cell cycle machinery in term explants, thought to
be physiologically senescent.53 Moreover, the PE-PDMSCs
induced phenotype observed in our model strongly resembles
that of severe early onset preeclamptic placentae, characterized
Figure 7. Cyclin D1 spatial localization in physiological placental villous explants treated with culture media conditioned by normal or PE-PDMSC. (A) Absence of positive
immunoreactivity for Cyclin D1 in section stained with control IgG. B) Cyclin D1 spatial localization in physiological villous explants treated with unconditioned media
(CTRL, n D 4 explants) assessed by immunofluorescent staining. C) Cyclin D1 spatial localization in physiological villous explants treated with media conditioned by nor-
mal (N CM, n D 4 explants) assessed by immunofluorescent staining. C) Cyclin D1 spatial localization in physiological villous explants treated media conditioned by with
preeclamptic (PE CM, n D 4 explants) assessed by immunofluorescent staining. Cell nuclei are showed in blue by DAPI signal. TR, trophoblast cells; M, mesenchyme; V,
vessel. Original magnifications, x40.
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by hyperproliferative immature trophoblast cells associated to
increased trophoblast cell death.7 In contrast, increased senes-
cence and reduced proliferation levels were described in late
onset PE and FGR placentae, suggesting an accelerated aging
process in these pathological tissues.30,53 Future investigations
should be directed to clarify these key cell cycle regulation dif-
ferences between early and late onset PE-FGR placentae.
Our data are in line with previous studies that demonstrated
the direct involvement of mesenchymal stromal cells in the
pathogenesis of several disorders. For example, breast cancer
progression and metastasis are promoted by MSCs resident in
the tumor niche and we previously described that preeclamptic
PDMSCs possess a pro-inflammatory and anti-angiogenic phe-
notype, thus contributing to the pathogenesis of PE.9 Neverthe-
less, the described anomalies in PE-PDMSCs could not be a
cause but a consequence of preeclampsia. In fact, the adverse
stromal microenvironment could alter the properties and tro-
phic actions of the derived MSC.9,54
Next, we focused on Cyclin D1 immunolocalization because
it was reported that its subcellular localization regulated
entirely p16INK4A/p18INK4C-CDK4/CDK6 pathway.55 Previ-
ous data from De Loia and collegues showed that Cyclin D1
protein was present in endothelial cells lining the villous blood
vessels.20 In contrast, we reported that Cyclin D1 was mainly
expressed in the syncytiotrophoblast layer and less in the peri-
vascular area and mesenchyme. In line with our data, De Falco
and colleagues described a strong trophoblast Cyclin D1 posi-
tivity.55 In particular, we found a stronger cytoplasmic Cyclin
D1 signal. It was shown that Cyclin D1 accumulates in the
nucleus throughout G1 phase and relocate in the cytoplasm
during the interphase and cell cycle progression.56,57 Cyclin D1
subcellular distribution is a finely tuned equilibrium between
nuclear importation and exportation and its overexpression
always indicates a cell proliferation advantage.55,58 Thus, PE
PDMSCs-CM induced syncytiotrophoblast Cyclin D1 accumu-
lation highlights the ability of preeclamptic mesenchymal cells
to induce a PE-like hyper-proliferative phenotype in physiolog-
ical placentae by the secretion of trophic mediators.
In conclusion, altered Cyclin D1-p16INK4A/p18INK4C
pathway in PE-PDMSCs could cause and/or be the consequence
of the adverse environment in which mesenchymal cells develop
during the early stages of placenta development, thus contribut-
ing to the aberrant villous architecture typical of preeclampsia.
Due to their ability to interfere cell cycle modulators in neigh-
boring cells, PDMSCs could represent a future therapeutic tool
or target for human placenta-related disorders as preeclampsia.
Patients and methods
Ethics statement
The study was approved by the Institutional Ethical Committee
of O.I.R.M. S.Anna Hospital and “Ordine Mauriziano di Tor-
ino” (n.209; protocol 39226/C.27.1 04/08/09) (Turin, Italy). All
patients provided written informed consent.
Study population
The study population included 20 physiological term preg-
nancies and 24 singleton pregnancies complicated by severe
preeclampsia with fetal-placental compromise. We deliber-
ately selected only those PE cases characterized by anoma-
lies at the fetal-placental district since we were interested in
specifically investigating the features of those mesenchymal
cells resident in the chorionic villi of pathological placentae.
The diagnosis of PE was made according to the following
criteria: presence of pregnancy-induced hypertension (sys-
tolic blood pressure  140 mmHg or diastolic blood pres-
sure  90 mmHg) and proteinuria (> 300 mg/24 h) after
20 week of gestational age in previously normotensive
women. Fetal-placental compromise was defined as the
presence of one or more of the following features: a) Fetal
Growth Restriction (FGR), defined as birth weight below
the fifth centile according to the Italian growth curves nor-
malized for gestational age and sex59,60; b) pathological
umbilical artery Doppler waveforms (absent or reverse end
diastolic flow - A/REDF); c) increased resistance to flow in
maternal uterine arteries (early diastolic notch or pulsatility
index - PtdIns - higher than 0.58).This rigorous classifica-
tion allowed us to distinguish between maternal and placen-
tal PE since placentae are significantly different in these 2
groups When one or more of the above variables are abnor-
mal, preeclampsia is defined of placental origin. If we used
the common “early and late PE” classification there would
have been a mixed population of maternal and placental
preeclampsia in each group.61
Control patients were singleton term physiological normo-
tensive pregnancies with no signs of preeclampsia or FGR. We
did not use “age-matched” control pregnancies since no pre-
term delivery is physiological. Exclusion criteria were: congeni-
tal malformation, chromosomal abnormalities (in number and/
or structure), maternal and/or intrauterine infections, cardio-
vascular diseases and metabolic syndrome.
Placental-derived mesenchymal stromal cells (PDMSCs)
PDMSCs were isolated from normal and PE placental basal
plate by enzymatic digestion and gradient as previously
described.9 Briefly, after decidua removal, placenta basal plate
specimens were cut into pieces of approximately 30 g and
washed several times with Hank’s Buffered Salt Solution
(HBSS, Life Technologies, Cat. No. 14110046). Next, the pla-
cental tissues were mechanically minced and processed by
enzymatic digestion using 100U/ml collagenase type I (Life
Technologies, Cat. No.17100017) plus 5 mg/ml DNAse I (Life
Technologies, Cat. No. 18047019) for 3 hours at 37C, fil-
tered and then processed by density gradient using 1.073
Ficoll Paque Premium (GE Healthcare Europe, Cat. No.
geh17544652). PDMSCs were collected from the interphase
and washed. Finally, cell counts was performed using an
automated cell analyzer (Scepter 2.0 Cell Couter, Merk-Milli-
pore) and PDMSCs were resuspended in Dulbecco’s modified
Minimum Essential Medium (DMEM, Life Technologies,
Cat. No. 11880028) supplemented with 10% Fetal Bovine
Serum (FBS Australian origin, Life Technologies, Cat. No.
10099141) in T150 flask maintained at 37 C and 5% CO2.
Normal and PE-PDMSCs were characterized at passage 3 by
flow cytometry using the following markers panel: HLA-I,
HLA-DR, CD34, CD133, CD20, CD326, CD31, CD45 and
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CD14 (Miltenyi Biotech, Cat. No. 130095198). Moreover,
Oct-4 and Nanog expression was evaluated in normal and
PE-PDMSCs by semi-quantitative RT-PCR as markers of
stemness. Primers were designed as previously described.9
Preparation of PDMSCs conditioned media (CM)
At passage 3, normal and PE-PDMSCs were plated in 6 well
plates at a density of 1 £ 105 cells/ml in DMEM LG without
FBS. PDMSCs conditioned media were then collected at
48 hours of culture and filtered by a 0.22 mm filter (Merck-
Millipore, Italy) to remove cellular debris. Cells were harvested
and processed for mRNA and protein isolation.
Treatment of physiological villous explants with PDMSCs
CM
We next evaluated the paracrine effects of normal and PE
PDMSCs-CM on physiological placental villous explants. This
model allowed us to determine the sequence of molecular events
in tissues characterized by conserved physiological pathways,
thus avoiding biases due to previous existing pathological anom-
alies. Biopsies from 2 different physiological term placentae (nD
30 explants for each placenta) were separated from the placental
basal plate and small portions of chorionic villi were excised and
cultured in 24-well plates in HAM F-12 Nutrient Medium
(Gibco, Invitrogen Life Techonologies, Cat. No. 21765029) at
37C - 5% CO2 - 20% O2 overnight. Explants, composed by
trophoblast, mesenchymal and endothelial cells, were used as
model of organized placental tissue. Next, the medium was
removed and explants were treated for 72 h with 500 ml of CM
by 4 different normal PDMSCs lines (n D 20 explants) and by 4
different PE-PDMSCs lines (n D 20 explants). Explants treated
by unconditioned culture media were used as controls (n D 20
explants). Explants were finally immediately fixed for histologi-
cal analyses (4 for each experimental condition) or frozen for
RNA and protein isolation (nD 48).
Lactate dehydrogenase (LDH) cytotoxicity assay
Cytotoxicity of CMs treatment on villous explants was
determined by LDH-Cytotoxicity colorimetric assay (Biovi-
sion Inc., Cat. No. K726–500) performed using 72h explants
supernatant according to the manufacturer’s instructions.
Explants treated by Triton X-100 and by unconditioned cul-
ture media for 8 h were used as high (H, 100%) and low
controls (0%) respectively. The positive control (C) was
provided by the manufacturer to test whether all reagents
were working properly responding to active LDH enzyme.
The absorbance at 450 nm was measured using a plate
reader spectrophotomether. Percent cytotoxicity values were
determined based on the amount of LDH released from 30-
min readings, as follows: (test sample – low control) / (high
control-low control) £ 100. The cut-off values for the LDH
assay was determined by the 2 £ SD rule where the thresh-
old is defined as 2 £ SD beyond the mean of the screened
samples. Values equal or exceeding the threshold were con-
sidered as sign of cytotoxicity.
RNA isolation and real time PCR
Total RNA was isolated from normal and PE-PDMSCs and vil-
lous explants using TRIzol reagent (Life Technologies, Invitrogen,
Cat. No. t9424) according to manufacturer instructions. Genomic
DNA contamination was removed by DNase I digestion before
RT-PCR. cDNA was generated from 5 mg of total RNA using a
random hexamers approach and RevertAid HMinus First Strand
cDNA Synthesis kit (Fermentas, Cat.No k1632).
Gene expressions levels of JunB, CyclinD1, p16INK4A,
p18INK4C, CDK4, CDK6 and PARP1 were determined by Real
Time PCR using specific TaqMan primers and probes (Life
Technologies, Cat. No 4331182). mRNA levels were normalized
using endogenous 18s as internal reference (Life Technologies,
Cat. No 4333760F). Relative expression and fold change were
calculated according to Livak and Schmittgen.62
Western blot analyses
Total proteins were isolated from PDMSCs and chorionic vil-
lous explants using 1X Radio Immuno-precipitation Assay
(RIPA) buffer. Thirty mg of total protein from PDMSCs and
villous explants were processed by SDS-page on 4–20% and
7.5% polyacrylamide pre-cast gradient gels (Bio-Rad Laborato-
ries S.r.l., Cat. No. 456–1099 and 4561034). Next, proteins were
transferred on PVDF membranes and probed at room temper-
ature with primary antibodies using the SnapID system (Merk-
Millipore, Italy) following manufacturer instructions. Primary
antibodies were: rabbit polyclonal anti-human JunB (1:2000
dilution, Merk-Millipore, Cat. No. 07–1333), mouse monoclo-
nal anti-human Cyclin D1 (1:1500 dilution, Cell Signaling, Cat.
No. 2978), rabbit monoclonal anti-human p16INK4A (1:250
dilution, Cell Signaling, Cat.No 4824), mouse monoclonal anti-
human p18INK4C (1:250 dilution, Cell Signaling, Cat.No 2896),
mouse monoclonal anti-human CDK4 (1:500 dilution, Cell Sig-
naling, Cat.No 12790), mouse monoclonal anti-human CDK6
(1:500 dilution, Cell Signaling, Cat. No. 3136), mouse monoclo-
nal anti-human PARP1 (1:500 diluition, Abcam, Cat. No.
ab110915) and mouse monoclonal anti-human b-actin (1:1000,
Sigma-Aldrich, Cat.No. A5316). Biotinylated secondary anti-
bodies were goat anti-mouse for Cyclin D1, p18INK4C, CDK4,
CDK6, PARP1 and b-actin (1:1000 dilution, Vector Laborato-
ries, Cat.No. sc-2005), donkey anti-rabbit for JunB and
p16INK4A (1:1000 dilution, Vector Laboratories, Cat.No. sc-
2004). Protein signals were detected by chemoluminescence
using LuminataTM Crescendo Western HRP reagent (Milli-
pore, Cat.No wbluc0100).
Cyclin D1 immunofluorescence staining
Villous explants treated by unconditioned medium (n D 4
explants) and with normal (n D 4 explants) or PE PDMSCs
CM (n D 4 explants) were fixed in 4% paraphormaldehyde and
embedded in paraffin. Sodium citrate antigen retrieval was per-
formed, followed by Sudan Black treatment (0.1% Sudan Black
in 70% EtOH) to quench endogenous fluorescence. Sections
were pre-incubated in 5% horse serum in PBS (contained
0.04% sodium azide and 0.008% gelatin) to block nonspecific
binding and incubated with primary antibodies overnight at
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4 C. Mouse polyclonal antibodies anti-human CyclinD1 (1:100
dilution; Cell Signaling, Cat. No. 2978) was used. Control IgG
were used as negative controls. Slides were treated with 0.4%
DAPI (40,6-diamidino-2-phenylindole) for nuclear detection.
Fluorescence images were viewed and captured using a confocal
microscope (Nikon D-Eclipse C1, Nikon, Chiyoda, Tokyo,
Japan).
Statistical analysis
All data are represented as mean§ standard error (SE). For com-
parison of data between multiple groups, used one-way analysis
of variance (ANOVA) with posthoc Dunnett’s test was used. For
comparison between 2 groups paired and unpaired Student’s t-
test were used as appropriate. Categorical variables are presented
as frequencies (percentages) and the comparison between differ-
ent groups was done with x2 by means of a 2 £ 2 or 2 £ 3 con-
tingency table; Fisher’s exact test was used for small sample sizes.
Statistical test were performed using SPSS Version 18 statistical
software and significance was accepted at P< 0.05.
Abbreviations
A/REDF absent or reverse end diastolic flow




FBS Fetal Bovine Serum
FGR Fetal Growth Restriction
HBSS Hank’s Buffered Salt Solution
IF Immuofluorescence
LDH Lactate dehydrogenase
PDMSCs Placental derived Mesenchymal Stromal Cells
PE Preeclamptic
PI Pulsatility Index
PARP1 Poly (ADP-ribose) polymerase 1
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